“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
HOME > COLUMN
COLUMN
-
What to Do about the Feeling of Torschlusspanik?
October 27, 2017
-
Women! Rock the Boat and Get Promoted
September 22, 2017
-
Getting the Right Message
August 25, 2017
-
Putting on Your Pants
July 21, 2017
-
Reputable Combination
July 11, 2017
-
What Is the Best Path to Customers’ Hearts and Minds?
June 19, 2017
-
Doubling Down on Digital
May 26, 2017
-
Global Opportunities for Global Minds
April 21, 2017
-
Will Tepid Pricing Debate Only Go Full-Throttle after Golden Week Holidays?
March 30, 2017
-
Some Japanese Pharmaceutical Workers May Slowly Be Working Themselves to Death
March 17, 2017
-
The Best Recruiters Are Just a Little Paranoid
February 17, 2017
-
5 Killer Questions for HR to Ask Recruiters
January 20, 2017
-
What Pharma Can Learn from the Airline Industry
December 16, 2016
-
Near Death at Singapore General Hospital and 5 Lessons I Learnt
October 20, 2016
-
Reasons for a “Hold”
August 9, 2016
-
It’s Time for Market Access to Play a Leading Role
April 22, 2016
-
Biosimilars Are the New Black
March 25, 2016
-
Technology Provides Opportunities for Medical Device Companies
February 18, 2016
-
Don’t Accept the Offer
January 22, 2016
-
It’s Your Choice
December 18, 2015
ページ
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…